A GPIIb/IIIa antagonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Tirofiban (hydrochloride hydrate)

Item No. 23392

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine, monohydrochloride, monohydrate
CAS Number
150915-40-5
Molecular Formula
C22H36N2O5S • HCl [H2O]
Formula Weight
495.1
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 30 mg/mlEthanol:PBS (pH7.2)(1:20): 0.05 mg/ml
λmax
228, 277 nm
SMILES
O=C(O)[C@@H](NS(CCCC)(=O)=O)CC1=CC=C(OCCCCC2CCNCC2)C=C1.Cl.O
InChi Code
InChI=1S/C22H36N2O5S.ClH.H2O/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18;;/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26);1H;1H2/t21-;;/m0../s1
InChi Key
HWAAPJPFZPHHBC-FGJQBABTSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $28

    Add

    5 mg

    $118

    Add

    10 mg

    $218

    Add
    Product Description

    Tirofiban is a potent nonpeptide glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; IC50 = 5 nM in a radioligand binding assay).1 It inhibits GPIIb/IIIa-dependent platelet aggregation with an IC50 value of 11 nM. Tirofiban is selective for platelet GPIIb/IIIa, only inhibiting human umbilical vein endothelial cell (HUVEC) attachment to microtiter plates containing fibrinogen (Fg), human vitronectin (Vn), or human fibronectin (Fn) at concentrations >10,000-fold above the IC50 for platelet aggregation. Tirofiban (300 and 1,000 μg/kg per minute, i.v.) prevents occlusive thrombosis and reduces thrombus mass in a canine model of electrically-induced coronary artery occlusive thrombosis.2 Formulations containing tirofiban have been used to prevent thrombotic occlusion associated with coronary angioplasty.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Hartman, G.D., Egbertson, M.S., Halczenko, W., et al. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35(24), 4640-4642 (1992).

    2. Lynch, J.J., Jr., Cook, J.J., Sitko, G.R., et al. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. J. Pharmacol. Exp. Ther. 272(1), 20-32 (1995).

    3. Investigators, T.R. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96(5), 1445-1453 (1997).